Reconciled ClinicalTrials.gov v2 Protocol Specification
| Protocol Field | Verified Registry Value |
|---|---|
| NCT Identifier | NCT06393374 |
| Consolidated Lead Sponsor | Merck & Co. |
| Therapeutic Condition Cohort | Oncology and Hematology |
| Clinical Trial Phase | Phase III |
| Overall Recruitment Status | RECRUITING |
| Registered Enrollment | 1,530 participants (ESTIMATED) |
| Registered Start Date | 2024-06-24 |
| WhyStopped Classification | Not Stopped |
Named U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Site Profile |
|---|---|---|
| Yale Cancer Center and Smilow Cancer Hospital | New Haven, CT | Open Hospital Dossier -> |
| University of Michigan Rogel Cancer Center | Ann Arbor, MI | Open Hospital Dossier -> |
| Washington University and Siteman Cancer Center | Saint Louis, MO | Open Hospital Dossier -> |
| Mount Sinai Hospital and Icahn School of Medicine | New York, NY | Open Hospital Dossier -> |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Merck & Co. across sibling Meru public-data platforms.
Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.